MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3753
Released On: 4/7/2016
Views: 4511
Released On: 3/31/2016
Views: 3485
Released On: 3/24/2016
Views: 2846
Released On: 3/17/2016
Views: 2394
Released On: 3/11/2016
Views: 2215
Released On: 3/4/2016
Views: 2538
Released On: 3/3/2016
Views: 2235
Released On: 2/23/2016
Views: 3583
Released On: 2/12/2016
Views: 2568
Released On: 2/10/2016
Views: 2285
Released On: 2/9/2016
Views: 2434
Released On: 1/20/2016
Views: 4228
Released On: 1/14/2016
Views: 4694
Released On: 1/5/2016
Views: 2934
Released On: 12/18/2015
Views: 9250
Released On: 12/9/2015
Views: 2689
Released On: 12/3/2015
Views: 3133